EP
IGMS

Eversept Partners’s IGM Biosciences IGMS Stock Holding History

Eversept Partners’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,770
Closed -$549K – 74
2020
Q1 		$549K Sell
9,770
-54,830
-85% -$2.4M 0.14% 53
2019
Q4 		$2.47M Buy
+64,600
New +$1.62M 0.44% 42

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Eversept Partners's IGMS Position: Q2 2020 in Review

Eversept Partners sold out of IGM Biosciences (IGMS) in Q2 2020, closing a stake of 9,770 shares — an estimated $549K sold.

Eversept Partners first reported a position in IGMS in Q4 2019 and held it in 2 quarters. The position peaked at $2.47M in Q4 2019. 81 funds tracked by Wall St. Rank hold IGMS as of Q2 2020.

  • Eversept Partners reported no remaining IGM Biosciences position as of Q2 2020 after selling out during the quarter.
  • Eversept Partners sold 9,770 IGM Biosciences shares in Q2 2020, an estimated $549K.
  • Eversept Partners first reported a position in IGM Biosciences in Q4 2019 and held it in 2 quarters.
  • Eversept Partners's IGM Biosciences position peaked at $2.47M in Q4 2019.
  • 81 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2020.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.